Inclusion Criteria:

- Participants must have a diagnosis of chronic myelogenous leukemia as confirmed by
fluorescent In Situ Hybridization (FISH) for BCR/ABL translocation and/or standard
cytogenetics analysis.

- Participants may have received prior hydroxyurea but may not be currently being
treated with hydroxyurea at the time of study initiation.

- Participants may have received prior TKI therapy, however must be on a stable dose of
their current TKI for at least one month prior to enrollment.

- Participants must demonstrate evidence of persistent disease either by
cytogenetics/FISH or by PCR for BCR/ABL in the peripheral blood or bone marrow.

- Greater than or equal to 18 years in age. Because little dosing or adverse event data
are currently available on the use of Arsenic in participants <18 years of age,
children are excluded from this study.

- Life expectancy of greater than 3 months

- ECOG performance status <2

- Participants must have normal organ and marrow function as defined below:

- Bilirubin ≤ 2.0 mg/dL

- Creatinine ≤ 2 mg/dL

- ALT < 2.5 X institutional upper limit of normal

- AST < 2.5 X institutional upper limit of normal

- WBC > 2.0 K/uL

- Platelets >100K

- Oxygen saturation > 95% on room air

- The effects of Arsenic on the developing human fetus are unknown. For this reason,
women of child-bearing potential must have a documented negative pregnancy test; in
addition, agreement to use adequate contraception (hormonal or barrier method of
birth control; abstinence) must be documented for both women of child-bearing
potential and men prior to study entry and for the duration of study participation.
Should a woman become pregnant or suspect she is pregnant while participating in this
study, she should inform her treating physician immediately

- All patients must demonstrate the ability to understand the investigational nature of
this study and must sign a written informed consent document in accordance with
institutional and federal guidelines

Exclusion Criteria:

- History of acute myocardial infarction, unstable angina, congestive heart failure, or
arrhythmia within the last three months

- Participants may not be receiving any other study agent

- Mean QTc> 450 ms at time of screening

- Use of potassium wasting diuretics during study treatment

- Patients should not be taking drugs that are generally accepted to have a risk of
causing Torsades de Pointes. The following must be discontinued at least 7 days
prior to enrollment to be eligible: quinidine, procainamide, disopyramide,
amiodarone, sotalol, ibutilide, dofetilide, erythromycins, clarithromycin,
chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cisapride,
bepridil, droperidol, methadone, chloroquine, domperidone, halofantrine,
levomethadyl, pentamidine, sparfloxacin, lidoflazine

- Drugs that are highly dependent on CYP3A4 for metabolism and have a narrow
therapeutic index (see Appendix A) are allowed but must be used with caution

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Concurrent and or uncontrolled psychiatric or medical condition which may interfere
with the study completion.

- Pregnant women are excluded from this study because the risk of Arsenic to a
developing fetus is unknown. Because there is an unknown but potential risk of
adverse events in nursing infants secondary to treatment of the mother with Arsenic,
breastfeeding should be discontinued if the mother is treated on this clinical trial

- Individuals with a history of a different malignancy are ineligible except for the
following circumstances. Individuals with a history of other malignancies are
eligible if they have been disease-free for at least 5 years and are deemed by the
investigator to be at low risk for recurrence of that malignancy. Individuals with
the following cancers are eligible if diagnosed and treated within the past 5 years:
cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin

- HIV-positive individuals on combination antiretroviral therapy are ineligible because
of the potential for pharmacokinetic interactions with TKI therapy and Arsenic. In
addition, these individuals are at increased risk of lethal infections when treated
with marrow-suppressive therapy.